Clearmind Medicine (Nasdaq: CMND) launches MEAI-tirzepatide obesity study
Rhea-AI Filing Summary
Clearmind Medicine Inc. has signed a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem to study its compound MEAI (CMND-100) alongside tirzepatide in diet-induced obese mice. The 12‑month preclinical study will test MEAI both in combination with tirzepatide and as a maintenance therapy after tirzepatide treatment to assess weight regain and metabolic effects.
Earlier work with the same laboratory showed MEAI produced about 15–20% body weight reduction in obese mice, mainly by increasing energy expenditure and fat use while preserving lean mass. Clearmind positions MEAI as a non‑hallucinogenic, second‑generation neuroplastogen that could complement GLP‑1–based obesity therapies in a market estimated at $50–66 billion in 2025 and projected to reach $170–185 billion by 2033. The company also highlights an intellectual property portfolio of nineteen patent families, including 31 granted patents.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
GLP-1 medications medical
tirzepatide medical
diet-induced obese (DIO) mice medical
neuroplastogen-derived therapeutics medical
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Clearmind Medicine (CMND) announce in its latest 6-K filing?
What is the focus of Clearmind Medicine’s MEAI and tirzepatide study?
How effective was MEAI in Clearmind Medicine’s prior preclinical research?
How large is the GLP-1 and tirzepatide market Clearmind targets with MEAI?
What is Clearmind Medicine’s core business focus as described in the filing?
What intellectual property position does Clearmind Medicine (CMND) report?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: May 2026
Commission file number: 001-41557
CLEARMIND MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Attached hereto and incorporated herein is the Registrant’s press release issued on May 18, 2026, titled “Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications”.
The first four paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
EXHIBIT INDEX
| Exhibit No. | ||
| 99.1 | Press release titled: “Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Clearmind Medicine, Inc. | ||
| (Registrant) | ||
| Date: May 18, 2026 | By: | /s/ Adi Zuloff-Shani |
| Name: | Adi Zuloff-Shani | |
| Title: | Chief Executive Officer | |
3
Exhibit 99.1
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the signing of a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. The agreement will fund a comprehensive preclinical study evaluating the metabolic efficacy of MEAI (CMND-100), both in combination with and as a maintenance therapy following tirzepatide treatment in diet-induced obese (“DIO”) mice. The research will be conducted by Professor Joseph (Yossi) Tam and his team at the Obesity and Metabolism Laboratory at the Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem.
The global market for incretin-based therapies and tirzepatide has grown into a massive industry valued at approximately $50–66 billion in 2025, and is projected to reach $170–185 billion by 2033. These therapies have significantly advanced the treatment of obesity and type 2 diabetes, delivering substantial weight loss and cardiometabolic improvements. Despite their remarkable success, GLP-1 and dual GLP-1/GIP receptor agonists primarily work by suppressing appetite and reducing energy intake. A major clinical challenge remains: substantial weight regain- often 25% or more of the lost weight within one year, along with partial reversal of metabolic benefits, frequently occurs upon discontinuation. This underscores the urgent need for complementary or maintenance strategies that can enhance treatment durability, help preserve lean muscle mass, and actively boost energy expenditure.
Building on positive results from its prior collaboration with Professor Yossi Tam’s laboratory at the Hebrew University, where MEAI demonstrated approximately 15–20% body weight reduction in DIO mice, primarily through increased energy expenditure and fat utilization while preserving lean mass and improving glucose homeostasis and hepatic steatosis, Clearmind is now advancing MEAI into combination and sequencing strategies with today’s leading incretin therapy.
The new 12-month study, titled “Assessing the Metabolic Efficacy of MEAI in Combination and Sequencing with Tirzepatide in Diet-Induced Obese Mice,” will examine: Additive or synergistic effects when MEAI is administered concomitantly with tirzepatide and the potential of MEAI as a maintenance therapy to attenuate post-tirzepatide weight regain and preserve metabolic benefits across multiple doses.
“MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies,” said Dr. Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine. “While those drugs excel at reducing food intake, our previous preclinical data show MEAI significantly enhances energy expenditure. We believe that this combination and maintenance approach has potential to deliver more robust, durable, and clinically meaningful outcomes for patients.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor
Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of the global market for incretin-based therapies, how Clearmind is advancing MEAI into combination and sequencing strategies with today’s leading incretin therapy, how MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies and its belief that the combination and maintenance approach of MEAI and incretin therapies has potential to deliver more robust, durable, and clinically meaningful outcomes for patients. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.